MAPT and Alzheimer disease: Furthermore, the EMIF-AD 90+ Study is one of the first studies that collects a broad range of markers of neurodegeneration in the oldest-old, including an amyloid PET scan, amyloid β and tau measured in CSF and blood and neurophysiological measures.